AiRuiJing (zeprumetostat) / Jiangsu Hengrui Pharma, Treeline Biosci - LARVOL DELTA

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Trial primary completion date: Jun 2026 ➔ Dec 2026

Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Retlirafusp alfa Combined with Rivoceranib, With or Without Zeprumetostat, in Patients with Advanced Gastric Cancer Who Have Failed First-Line Immunotherapy (ESMO 2026) - No abstract available

Clinical • Metastases • Gastric Cancer • Oncology • Solid Tumor

ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITOR SHR2554 IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL): UPDATED OUTCOMES FROM THE FIRST-IN-HUMAN PHASE 1 STUDY (ICML 2023) - P1 | "This extended follow-up analysis further provides evidence of potent anti-tumor activity, durable response, and acceptable safety of SHR2554 in pts with r/r PTCL."

P1 data • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

A PIVOTAL STUDY OF SHR2554, AN ORAL INHIBITOR AGAINST ENHANCER OF ZESTE HOMOLOG 2 (EZH2), IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL) (EHA 2025) - P1, P3 | "All patients had received chemotherapy regimens; moreover, all patients had been treated with tucidinostat or brentuximab vedotin (tucidinostat, 59 [88.1%]; brentuximab vedotin, 21 [31.3%]; both, 13 [19.4%]). The pivotal study met its primary endpoint, demonstrating that SHR2554 is efficacious and has a manageable safety profile in patients with r/r PTCL. Our findings position SHR2554 as a new potential therapeutic option for this challenging-to-treat population. A randomized controlled phase 3 study comparing SHR2554 with standard therapy for r/r PTCL is currently underway (ClinicalTrials.gov, NCT06122389)."

Anemia • Hematological Disorders • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • EZH2

SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL) (clinicaltrials.gov) - P1/2 | N=44 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China

New P1/2 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL (clinicaltrials.gov) - P1/2 | N=33 | Not yet recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

New P1/2 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

An Exploratory Clinical Study of Adebrelimab in Combination with SHR-2554 in Patients with Non-Small Cell Lung Cancer with Inactivated SWI/SNF Complex Proteins or Related Gene Mutations (ChiCTR) - P2 | N=20 | Not yet recruiting | Sponsor: Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • ARID1A • EGFR • SMARCA2 • SMARCB1

SYSTEM: Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

IO biomarker • New P2 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer • HER-2

G08: New Genotype-guided Treatment in Newly Diagnosed PTCL (clinicaltrials.gov) - P1/2 | N=108 | Not yet recruiting | Sponsor: Ruijin Hospital

New P1/2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China

New P1 trial • Hematological Malignancies • Leukemia • Oncology • T-Cell Large Granular Lymphocyte Leukemia

EpiRev-NKT: Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma (clinicaltrials.gov) - P1/2 | N=107 | Recruiting | Sponsor: Rong Tao | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

PHASE IB STUDY OF SHR0302 PLUS SHR2554 IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA: SAFETY RUN-IN AND INITIAL EFFICACY (EHA 2026) - P2 | "Summary/Conclusion SHR0302 plus SHR2554 demonstrated manageable safety without observed DLTs and showed initial antitumor activity in R/R PTCL. Completion of stage-1 evaluations across dose levels and further follow-up are ongoing to inform RP2D selection and subsequent study stages."

Clinical • P1 data • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

CUREFL03: Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting ➔ Recruiting

Enrollment open • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: Sun Yat-sen University

New P1/2 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS (clinicaltrials.gov) - P2 | N=180 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Soochow University

New P2 trial • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

CUREFL03: Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China

New P2 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS (clinicaltrials.gov) - P2 | N=160 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Soochow University

New P2 trial • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

MA-GC-II-022: PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer (clinicaltrials.gov) - P2 | N=78 | Recruiting | Sponsor: The First Affiliated Hospital of Zhengzhou University | N=36 ➔ 78

Enrollment change • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Solid Tumor

EpiRev-NKT: Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma (clinicaltrials.gov) - P1/2 | N=107 | Not yet recruiting | Sponsor: Rong Tao

New P1/2 trial • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL (clinicaltrials.gov) - P1/2 | N=86 | Not yet recruiting | Sponsor: Ruijin Hospital

New P1/2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: Fudan University | Trial primary completion date: Feb 2026 ➔ Feb 2027

Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (clinicaltrials.gov) - P2 | N=218 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Clinical Study on the Efficacy and Safety of Zeprumetostat, Azacitidine Combined with Lipo-MIT in Relapsed/Refractory Peripheral T-Cell Lymphoma. (ChiCTR) - P2 | N=26 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University

New P2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL (clinicaltrials.gov) - P2 | N=26 | Recruiting | Sponsor: The First Affiliated Hospital of Soochow University

New P2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University

New P2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma